Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15769508 | 0.88 | MCHR1 (0.57) | MCHR1CYP3A4 | |
| SCHEMBL15769729 | 0.88 | MCHR1 (0.43) | MCHR1DRD4DRD2DRD3CYP3A4 | |
| SCHEMBL15769095 | 0.85 | MCHR1 (0.38) | MCHR1P2RX3ESR2 | |
| SCHEMBL15769455 | 0.85 | MCHR1 (0.44) | MCHR1 | |
| SCHEMBL11424854 | 0.83 | MCHR1 (0.62) | MCHR1HDAC1HDAC6CYP3A4 | |
| SCHEMBL15769032 | 0.83 | MCHR1 (0.54) | MCHR1CYP3A4 | |
| SCHEMBL15769134 | 0.82 | MCHR1 (0.54) | MCHR1CYP3A4 | |
| SCHEMBL15769594 | 0.82 | MCHR1 (0.56) | MCHR1CYP3A4 | |
| SCHEMBL11426954 | 0.82 | MCHR1 (0.55) | MCHR1P2RX3CYP3A4 | |
| SCHEMBL15781366 | 0.81 | ESR2 (0.38) | MCHR1ESR2GPR119MTHFD2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163012-A1 | PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIOPHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163012-A1 | PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIOPHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163012-A1 | PYRIDO-/AZEPINO-BENZOFURAN AND PYRIDO-/AZEPINO-BENZOTHIOPHENE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885P2RX3 1674/4885LIPG 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.